Oricell Closes $45M Series B1 Financing to Expand Development of Key Products
- Written by PR Newswire
SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), a China-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a $45M Series B1 investment round after the completion of a $125M Series B fund-raise in July 2022. The...
Read more: Oricell Closes $45M Series B1 Financing to Expand Development of Key Products